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Certain single nucleotide polymorphisms causing missense mutations in angiogenin result in its
loss-of-function and onset of amyotrophic lateral sclerosis (ALS). Although several such associations
are reported across diverse ethnic groups, no method is available for predicting if a new mutation is
deleterious. We present here a fast molecular dynamics based method for determining the mecha-
nisms of functional loss caused by mutations, and attributes to ascertain whether a mutation causes
ALS.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
ALS is a fatal progressive neurodegenerative disorder where the
selective loss of motor neurons in the spinal cord, brainstem and
cerebral cortex results in progressive paralysis and eventual death.
The etiology and mechanisms underlying this debilitating disease
are poorly understood. The most common cause of ALS has been
associated with mutations in SOD1, FUS/TLS, TARDBP and C9ORF72
genes, while mutations in VAPB, OPTN, FIG4, DAO and VCP cause
ALS in lesser frequency [1]. Genome wide association studies have
identiﬁed several single nucleotide polymorphisms (SNPs) across
different genes associated with ALS. Since the ﬁrst clinical study
initiated in Ireland by Greenway et al. [2], several SNPs encoding
missense mutations in the coding region of ANG have been identi-
ﬁed in ALS patients of Irish and Scottish background. Later studies
conﬁrmed the association of ANG mutations with ALS across di-
verse ethnic groups [3–14].
Human ANG gene encodes a 14.1 kDa monomeric angiogenin
protein (ANG), which is a member of the ribonuclease A superfam-
ily. Wild-type ANG (WT-ANG) induces neovascularization, protects
motor neurons from hypoxia, stimulates neurite outgrowth andpath-ﬁnding, expresses strongly in the human spinal cord, and
hence, acts as a neuroprotective factor [4]. Owing to the presence
of two functional sites such as the receptor binding site (60NKNGN-
PHREN68) and the nuclear localization signal (29IMRRRGL35),
WT-ANG exhibits its angiogenic functions. The ribonucleolytic
activity of ANG is governed by the catalytic triad residues His13,
Lys40 and His114. These three key functional sites of ANG are
shown in Supplementary Fig. 1. ANG mutants are associated with
ALS because these exhibit loss of either ribonucleolytic activity or
nuclear translocation activity or both of these functions [4]. Till
now, 19 missense mutations in ANG have been identiﬁed across
ALS patients of various ethnic origins making this one of the most
frequently mutated genes in ALS (Table 1). In addition, several rare
missense mutations in ANG such as G20S, P38R, R51H, P88H, R95L,
A98V and P123L (Supplementary Table 1) have been catalogued in
the Exome variant Server [15]. Although, the loss-of-functions of
some known ANG mutants have been investigated previously
using functional assay experiments and explicit solvent based
molecular dynamics (MD) simulations [5,6,16,17], the functional
role of the rare ANG mutations has not yet been studied.
Studies reporting identiﬁcation of novel gene mutation(s) in
certain ALS cases usually fails to establish the functional conse-
quences of those mutations and the reasons for disease association
[2,7–15,18]. A rapid and decisive method for predicting the
mechanisms of functional loss of ANG caused by these mutations
will be helpful for the clinicians and researchers for a better
Table 1
A comprehensive list of human angiogenin mutations reported in ALS patients, with their corresponding loss-of-functions data from implicit solvent MD simulations, explicit
solvent MD simulations and reported experimental ﬁndings. Simulations of (Q12L [7], C39W [7], K40I [7], and H114R [8]) were not performed because the mutational sites are
located proximal to or located at the catalytic triad with their obvious role in loss of ribonucleolytic activity; while simulations of (F-13S [8], F-13L [10], M-24I [8], P-4S [8]) were
not performed because these are located in the signal peptide region and not present in mature ANG.
Human ANG
mutation
His114
conformational
switching
H-bond path
mediated through
Leu115
Folding of 31RRR33 Ribonucleolytic activity Nuclear translocation activity
Implicit
MD
Explicit
MD
Implicit
MD
Explicit
MD
Implicit
MD
Explicit
MD
Implicit
MD
Explicit
MD
Experimental
reports
Implicit
MD
Explicit
MD
Experimental
reports
K17I [2] Yes Yes [16] Yes Yes [16] No No [16] Loss Loss [16] Loss[5,6,31] No loss No loss
[16]
No loss [5,31]
S28N [5] Yes Yes [16] Yes Yes [16] Yes Yes [16] Loss Loss [16] Loss [5,31] Loss Loss
[16]
Loss [5,31]
P112L [5] Yes Yes [16] Yes Yes [16] Yes Yes [16] Partial
loss
Partial loss
[16]
Partial loss
[5,31]
Loss Loss
[16]
Loss [5,31]
I46V [2] Yes Yes [17] Yes Yes [17] No No [17] Partial
loss
Partial loss
[17]
Partial loss
[6,31]
No loss No loss
[17]
No loss [31]
K17E [2] Yes Yes [17] Yes Yes [17] No No [17] Partial
loss
Partial loss
[17]
Partial loss
[6,31]
No loss No loss
[17]
No loss [31]
R31K [2] Yes Yes [17] Yes Yes [17] No No [17] Minor
loss
Minor loss
[17]
Minor loss
[6,31]
No loss No loss
[17]
No loss [6,31]
V113I [7] No No [16] No No [16] Yes Yes [16] No loss No loss
[16]
Minor loss
[31]
Loss Loss
[16]
Transient
activity [31]
R121H [8] No No [17] No No [17] Yes Yes [17] No loss No loss
[17]
No loss [31] Loss Loss
[17]
Transient
activity [31]
K54E [9] No No [17] No No [17] Yes Yes [17] No loss No loss
[17]
No loss [31] Loss Loss
[17]
Not reported
R121C [10] No No [17] No No [17] No No [17] No loss No loss
[17]
Not reported No loss No loss
[17]
Not reported
V103I [11] No No [17] No No [17] Yes Yes [17] No loss No loss
[17]
Not reported Loss Loss
[17]
Not reported
D22G [12] Yes Yes [17] Yes Yes [17] No No [17] Loss Loss [17] Not reported No loss No loss
[17]
Not reported
T80S [13] Yes Yes [17] Yes Yes [17] No No [17] Loss Loss [17] Not reported No loss No loss
[17]
Not reported
F100I [13] No No [17] No No [17] Yes Yes [17] No loss No loss
[17]
Not reported Loss Loss
[17]
Not reported
N49S [14] Yes Yes [17] Yes Yes [17] No No [17] Loss Loss [17] Not reported No loss No loss
[17]
Not reported
L35P [18] Yes Yes [16] Yes Yes [16] Yes Yes [16] Loss Loss [16] Not reported Loss Loss
[16]
Not reported
K60E [18] No No [16] No No [16] No No [16] No loss No loss
[16]
Not reported No loss No loss
[16]
Not reported
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gression. We present here a method that uses several attributes
of ANG that change speciﬁcally due to deleterious mutations.
These attributes can be calculated relatively quickly using an im-
plicit solvent MD simulation. Using this method it is possible to
accurately predict the mechanisms of loss-of-functions and if the
mutation is deleterious.
2. Materials and methods
2.1. Generalized Born solvent molecular simulations
Molecular dynamics simulations of the ANG mutants listed in
Table 1 and Supplementary Table 1 were carried out using the AM-
BER 10 package with the ff99SB force ﬁeld [19,20]. Crystal struc-
ture of human angiogenin (PDB: 1B1I) was used as the starting
structure and desired residues were mutated in silico keeping its
secondary structure intact [21]. Heteroatoms, cofactor CIT and
crystallographic water were removed a priori. Hydrogen atoms
were added using the Xleap tool of AMBER 10 and each system
was neutralized with Cl counter ions. The SANDER module imple-
mented in AMBER 10 was used for the simulations. Before the sim-
ulations, all the systems were relaxed by 2500 steps of steepest
descent followed by 1000 steps of conjugate gradient minimization
methods. Each system was subjected to gradual heating from 0 to
300 K in 200 ps followed by a constant temperature equilibrationfor 1000 ps at 300 K. 25 ns production MD simulations were car-
ried out with periodic boundary conditions in the NPT ensemble
at a temperature of 300 K with Berendsen temperature coupling
and a constant pressure of 1 atm with isotropic molecule-based
scaling [22]. SHAKE algorithm and particle-mesh Ewald (PME)
method were used to constrain bond lengths involving bonds to
hydrogen(s) and calculation of long range electrostatic forces,
respectively [23,24]. Generalized Born model was used to model
the solvation effects implicitly. For implicit solvent MD simula-
tions, the GB model proposed by Onufriev, Bashford, and Case
(igb = 5) and the analytical linearized Poisson–Boltzmann (ALPB)
approximations were used [25,26]. The Born radii were adopted
from Bondi with modiﬁcation (mbondi2). The trajectory of each
system was recorded at every 1 ps and convergence monitored.
Analysis of simulation results were carried out using PTRAJ module
implemented in AMBER 10. SUNMicrosystems cluster (320 proces-
sors) at the Supercomputing Facility for Bioinformatics and Com-
putational Biology (http://www.scfbio-iitd.res.in) of Indian
Institute of Technology Delhi was used for performing the MD sim-
ulations of WT-ANG and 24 ANG mutants.
2.2. Molecular docking simulations
ParDOCK was used for carrying out the docking simulations of
WT-ANG and each mutant with NCI-65828, which is an inhibitor
of ribonucleolytic activity of ANG [27]. ParDOCK is an all atom
1764 A.K. Padhi et al. / FEBS Letters 587 (2013) 1762–1766energy based Monte Carlo docking protocol, which requires a ref-
erence complex (target protein bound to a reference ligand) and
a candidate molecule along with speciﬁc mention of the centre of
mass of the cavity on which the ligand is to be docked. The active
sites of each of the mutant protein were computed using the Active
Site Prediction server (http://www.scfbio-iitd.res.in/dock/Active-
Site.jsp), which computes cavities in the protein, which act as the
potential binding sites. Molecular docking was carried out with
the cavity that lies in closest proximity to His114 against com-
pound NCI-65828.
2.3. Solvent accessible surface area
SASA of nuclear localization signal residues of ANG, 31RRR33,
was calculated using MolSpace (http://www.compbiochem.org/
Software/molspace/Home.html), a Plug-in for Visual Molecular
Dynamics (VMD) software (version 1.9.1) [28] for the entire simu-
lation time course. A probe radius of 1.4 Å was used for the calcu-
lation of SASA for WT-ANG and mutants.Fig. 1. An illustration of the three global attributes to determine deleterious ANG muta
stability of His114 which retains its native conformation and ribonucleolytic activity; (b)
conformational switching of His114 about 99 from its native conformation and hence re
mutant showing the hydrogen bond interaction path (green dashed lines) from the site
graph showing the difference in time proﬁle to carry out 1 ns simulation between explicit
MD simulations, that shows the loose packing of nuclear localization signal residues 31RR
taken from implicit MD simulations, that shows local folding of nuclear localization sig2.4. Data analysis and ﬁgure preparation
UCSF CHIMERA [29] package was used to compute the hydro-
gen bond interaction paths from each of the MD trajectories and
visualization of hydrogen bond interaction paths were achieved
using Cytoscape [30] (http://www.cytoscape.org/). Hydrogen
Bonds plug-in incorporated in VMD was used for the calculation
of percentage hydrogen occupancy values among pair of amino
acid residues from the simulation trajectories. All the ﬁgures for
representing ANG protein backbone and amino acid residues were
generated using PyMOL (http://www.pymol.org).
3. Results and discussion
We investigated the functional loss mechanisms of all reported
ANG mutations associated with ALS, and rare missense mutations
of ANG not yet known to be associated with ALS, and established
that certain structural and dynamical features are critical for deter-
mining the loss of ribonucleolytic activity and nuclear translocationtions. (a) Snapshot of WT-ANG taken from implicit MD simulations, that shows the
snapshot of ANG-K17I mutant taken from implicit MD simulations, that shows the
sulting in loss of its ribonucleolytic activity; (c) ribbon representation of ANG-K17I
of mutation (Ile17) to catalytic residue (His114) mediated through Leu115; (d) bar
and implicit solvent based simulations; (e) snapshot of WT-ANG taken from implicit
R33, retaining its nuclear translocation activity and (f) snapshot of ANG-S28N mutant
nal residues 31RRR33, consequently leading to loss of nuclear translocation activity.
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alytic residue His114 was responsible for loss of ribonucleolytic
activity in certain ANG mutants. The conformational switching of
His114 was further investigated and it was observed that shortest
hydrogen bond interaction path among amino acid residues from
the site of mutation to His114, mediated through Leu115 was
responsible for such conformational alterations. We also found that
higher hydrogen bond percentage occupancy among residues
His114–Ala106, Ala106–Val113 and Thr44–Thr80, Asp116–Ser118
was favorable for the observed conformational switching of
His114. In addition to this, the loss of nuclear translocation activity
of ANG mutants was due to reduction of solvent accessible surface
area (SASA) caused by local folding of nuclear localization signal
residues 31RRR33. These attributes can be rapidly determined using
implicit solvent-based MD simulations carried out for 25 ns
(Fig. 1a–f). We compared the computing time required for the pre-
diction of functional loss mechanisms of the implicit solvent MD
simulations with the explicit solvent MD simulations. It was ob-
served that the time required to carry out 1 ns simulation using im-
plicit solvent based simulations was about 100 min compared to
1560 min using explicit solvent based simulations on 16 CPUs
(Fig. 1d).
Crystal structure of ANG reveals that the catalytic triad com-
prising residues His13, Lys40 and His114 is responsible for the
ribonucleolytic activity. As most of the ANG mutants associated
with ALS are distal from the catalytic triad and still result in loss
of ribonucleolytic activity, the structural and dynamic changes of
the catalytic triad residues were visualized using VMD from each
MD trajectory. We evaluated the ﬁrst attribute: the conformational
switching of His114 to study the loss of ribonucleolytic activity. It
was observed that among the three catalytic residues, His114
exhibited a conformational change in K17I, S28N, P112L, I46V,
K17E, R31K, D22G, T80S, N49S, L35P, G20S, P38R, R51H, P88H
and R95L mutants (Fig. 1b, Supplementary Figs. 2A and 9). How-
ever, WT-ANG and other ANG mutants such as V103I, V113I,
R121C, R121H, K54E, F100I, K60E, A98V and P123L did not show
any conformational alteration (Fig. 1a, Supplementary Figs. 2B
and 9). The HA-CA-CB-CG dihedral angle change of His114 from
the native conformation (80 for WT-ANG) to an altered confor-
mation (179) for ALS associated ANG mutants K17I, S28N,
P112L, I46V, K17E, R31K, D22G, T80S, N49S, and, rare ANGmutants
L35P, G20S, P38R, R51H, P88H and R95L (Supplementary Figs. 3
and 10) indicate probable loss of ribonucleolytic activity. To ascer-
tain that the characteristic conformational change of His114 result
in loss of ribonucleolytic activity, several snapshots of ANG mu-
tants were obtained from simulation trajectories at both native
and altered His114 conformations and docked against NCI-65828,
a known inhibitor of ribonucleolytic activity of ANG. The binding
free energies averaged over the trajectories were found to be sig-
niﬁcantly lower for mutants possessing altered His114 conforma-
tion compared to WT-ANG and mutants retaining native His114
conformation. The binding energy scores for WT-ANG and mutants
are presented in Supplementary Table 2. These results correlated
with our previous reports and afﬁrmed that the observed confor-
mational change of His114 result in loss of ribonucleolytic activity
[16,17].
The second attribute is the presence of a hydrogen bond inter-
action path from the site of mutation to His114 mediated through
Leu115. We found that mutants exhibiting conformational switch-
ing of His114 (Supplementary Figs. 3 and 10), possessed a hydro-
gen bond interaction path (bond length cut-off 63.2 Å) mediated
through Leu115 (Fig. 1c, Supplementary Figs. 4 and 11). The impor-
tance of such selective amino acid residue mediated path for differ-
ent mutants is supported by published crystal structure of ANG,
which established Leu115 as a factor responsible for weak ribonuc-
leolytic activity [21]. Mutants V113I, R121C, R121H, K54E, F100I,A98V and P123L, which do not show any conformational switching
of His114, exhibited no hydrogen bond interaction path from the
site of mutation to His114. For other mutants K60E and V103I,
an alternative path from E60 and I103 to His114 was determined
(Supplementary Figs. 5 and 6). Apart from the hydrogen bond
interaction paths, higher percentage hydrogen bond occupancy be-
tween residues His114-Ala106, Ala106-Val113 and Thr44-Thr80,
Asp116-Ser118 is instrumental for observed conformational
change of His114. The percentage occupancy data for the mutants
are presented in Supplementary Table 3.
The third attribute is the reduction of SASA of nuclear localiza-
tion signal residues 31RRR33 due to its local folding over 25 ns sim-
ulation. We analyzed the change in accessible surface area for WT-
ANG and all the mutants listed in Table 1 and Supplementary Ta-
ble 1, and it was observed that mutants S28N, P112L, V103I,
V113I, R121H, K54E, F100I and L35P exhibited lower SASA values
(Supplementary Fig. 7B) compared to WT-ANG and mutants
K17I, I46V, K17E, R31K, D22G, R121C, T80S, N49S, K60E, G20S,
P38R, R51H, P88H, R95L, A98V and P123L (Supplementary
Figs. 7A and 12). It was noticed that the reduction of SASA of mu-
tants was due to local folding of 31RRR33 (Supplementary Fig. 8).
WT-ANG and mutants shown in Supplementary Figs. 7A and 12,
exhibited higher values of SASA as 31RRR33 was loosely packed
and possessed higher accessible surface area, while for mutants
shown in Supplementary Fig. 7B, we observed local folding and
close packing of 31RRR33 and hence lower SASA values (Fig. 1e
and f, Supplementary Figs. 8A, B and 13). These results correlated
with some of the known experimentally reported functional assay
data for mutants such as K17I, S28N, P112L, I46V, K17E, R31K,
V113I and R121H [5,31].
Further, for the mutants V103I, D22G, R121C, K54E, T80S, F100I,
N49S, L35P, K60E, G20S, P38R, R51H, P88H, R95L, A98V and P123L,
for which there is no experimental data available (Table 1 and Sup-
plementary Table 1), we predict by our method that mutants
V103I, K54E, F100I and L35P would exhibit loss of nuclear translo-
cation activity while mutants D22G, T80S, N49S, L35P, G20S, P38R,
R51H, P88H and R95L would exhibit loss of ribonucleolytic activity.
In addition, mutants R121C, K60E, A98V and P123L would not
show loss of either activities and are probably non-pathogenic.
The R121C-ANG mutation was identiﬁed in an Italian ALS patient
bearing the SOD1-G93Dmutation. Although previous reports show
that ALS patients with SOD1-G93D mutation exhibit slow disease
progression, this Italian patient died after 30 months of symptom
onset. This gave the impression that ANG-R121C mutation may
have accelerated the disease progression. However, our simulation
results show that R121C mutant did not exhibit loss of either ribo-
nucleolytic or nuclear translocation activities (Supplementary
Figs. 2B and 8A), suggesting some unknown mechanism possibly
enhanced the rapid disease progression [17].
In light of the reported experimental studies [5,6,16,17,31], and
from the results of this study, it appears that loss of either ribonuc-
leolytic activity or nuclear translocation activity due to an ANG
mutation is sufﬁcient to make it deleterious and cause ALS. At pres-
ent, however, we donot know whether a mutation exhibiting com-
plete loss of ribonucleolytic activity has a higher probability of
causing ALS than those exhibiting partial or minor loss of activity.
We deﬁned three attributes based on conformational change in
His114, hydrogen bond interaction path mediated through
Leu115 and the reduction of SASA due to folding of nuclear locali-
zation signal residues 31RRR33, for predicting if a mutation is dele-
terious or benign (Fig. 1). For a mutation to be deleterious, it must
score positive for conformational switching of His114 and the pres-
ence of the hydrogen bond interaction path mediated through
Leu115, or a reduction in SASA attribute. Otherwise, the mutation
is treated as non-pathogenic. These attributes can be calculated in
much lesser time (Fig. 1d) using implicit solvent MD simulations.
1766 A.K. Padhi et al. / FEBS Letters 587 (2013) 1762–1766Our simulation results correlate with reported experimental data
without exception [5,6,31]. To make this method widely accessible
to researchers and clinicians, we created a web server based tool,
ANGDelMut, freely available at http://bioschool.iitd.ernet.in/re-
search.htm. However, other functions may also play a role in ALS
physiopathology governed by receptor binding and DNA binding
domains [4] and could be included in future versions of
ANGDelMut.
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